[go: up one dir, main page]

PL2361085T3 - Zastosowanie przeciwciała anty-vegf w połączeniu z chemioterapią w leczeniu raka sutka - Google Patents

Zastosowanie przeciwciała anty-vegf w połączeniu z chemioterapią w leczeniu raka sutka

Info

Publication number
PL2361085T3
PL2361085T3 PL09764134T PL09764134T PL2361085T3 PL 2361085 T3 PL2361085 T3 PL 2361085T3 PL 09764134 T PL09764134 T PL 09764134T PL 09764134 T PL09764134 T PL 09764134T PL 2361085 T3 PL2361085 T3 PL 2361085T3
Authority
PL
Poland
Prior art keywords
chemotherapy
combination
breast cancer
vegf antibody
treating breast
Prior art date
Application number
PL09764134T
Other languages
English (en)
Other versions
PL2361085T5 (pl
Inventor
Gwendolyn Fyfe
See Chun Phan
Xian Zhou
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42154236&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2361085(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PL2361085T3 publication Critical patent/PL2361085T3/pl
Publication of PL2361085T5 publication Critical patent/PL2361085T5/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PL09764134T 2008-11-22 2009-11-20 Zastosowanie przeciwciała anty-vegf w połączeniu z chemioterapią w leczeniu raka sutka PL2361085T5 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11710208P 2008-11-22 2008-11-22
US17800909P 2009-05-13 2009-05-13
US17930709P 2009-05-18 2009-05-18
EP09764134.4A EP2361085B9 (en) 2008-11-22 2009-11-20 Use of anti-vegf antibody in combination with chemotherapy for treating breast cancer
PCT/US2009/065381 WO2010059969A2 (en) 2008-11-22 2009-11-20 Anti-angiogenesis therapy for the treatment of breast cancer

Publications (2)

Publication Number Publication Date
PL2361085T3 true PL2361085T3 (pl) 2015-08-31
PL2361085T5 PL2361085T5 (pl) 2018-12-31

Family

ID=42154236

Family Applications (2)

Application Number Title Priority Date Filing Date
PL09764134T PL2361085T5 (pl) 2008-11-22 2009-11-20 Zastosowanie przeciwciała anty-vegf w połączeniu z chemioterapią w leczeniu raka sutka
PL13189711T PL2752189T3 (pl) 2008-11-22 2009-11-20 Zastosowanie przeciwciała anty-VEGF w połączeniu z chemioterapią do leczenia raka sutka

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL13189711T PL2752189T3 (pl) 2008-11-22 2009-11-20 Zastosowanie przeciwciała anty-VEGF w połączeniu z chemioterapią do leczenia raka sutka

Country Status (28)

Country Link
US (5) US20100143351A1 (pl)
EP (3) EP2752189B1 (pl)
JP (4) JP6041489B2 (pl)
KR (3) KR20170015525A (pl)
CN (2) CN105214086B (pl)
AR (1) AR074203A1 (pl)
AU (1) AU2009316409A1 (pl)
BR (1) BRPI0916138A2 (pl)
CA (1) CA2744158A1 (pl)
CL (1) CL2011001186A1 (pl)
CY (1) CY1118549T1 (pl)
DK (2) DK2361085T4 (pl)
ES (2) ES2611337T3 (pl)
HR (1) HRP20170059T1 (pl)
HU (2) HUE024872T2 (pl)
IL (2) IL212998A (pl)
LT (1) LT2752189T (pl)
MX (2) MX2011005383A (pl)
PH (1) PH12014502507A1 (pl)
PL (2) PL2361085T5 (pl)
PT (1) PT2752189T (pl)
RU (1) RU2531948C2 (pl)
SG (1) SG171780A1 (pl)
SI (2) SI2752189T1 (pl)
SM (1) SMT201700173T1 (pl)
TW (2) TWI612971B (pl)
WO (1) WO2010059969A2 (pl)
ZA (1) ZA201103321B (pl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE055911T2 (hu) 2008-05-15 2021-12-28 Celgene Corp Citidin-analógokat tartalmazó orális készítmények, és eljárások azok alkalmazására
EP2752189B1 (en) * 2008-11-22 2016-10-26 F. Hoffmann-La Roche AG Use of anti-vegf antibody in combination with chemotherapy for treating breast cancer
RU2012140447A (ru) 2010-02-23 2014-03-27 Дженентек, Инк. Антиангиогенная терапия для лечения рака яичника
ES3023516T3 (en) * 2011-10-14 2025-06-02 Hoffmann La Roche Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab
SG11201401946QA (en) 2011-11-01 2014-05-29 Celgene Corp Methods for treating cancers using oral formulations of cytidine analogs
SI2825558T1 (sl) 2012-03-13 2019-08-30 F. Hoffmann-La Roche Ag Kombinirana terapija za zdravljenje raka jajčnikov
RS59816B1 (sr) 2013-08-26 2020-02-28 Novartis Ag Nova primena
EA201690713A1 (ru) 2013-10-04 2016-08-31 Инфинити Фармасьютикалз, Инк. Гетероциклические соединения и их применения
SG11201607705XA (en) 2014-03-19 2016-10-28 Infinity Pharmaceuticals Inc Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
NZ727147A (en) * 2014-07-03 2018-05-25 Imclone Llc Combination therapy comprising olaratumab and doxorubicin
AU2015289798B2 (en) 2014-07-14 2019-09-12 University Of Utah Research Foundation In situ solidifying complex coacervates and methods of making and using thereof
CN104991065B (zh) * 2015-07-07 2017-01-11 复旦大学附属金山医院 一种用于诊断乳腺癌的三联标志物及其应用
CN114230571B (zh) 2015-09-14 2025-07-08 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
EP3397276A4 (en) 2015-12-30 2019-12-18 Kodiak Sciences Inc. ANTIBODIES AND CONJUGATES THEREOF
CN114984206A (zh) 2017-03-02 2022-09-02 基因泰克公司 Her2阳性乳腺癌的辅助治疗
WO2019084548A1 (en) * 2017-10-27 2019-05-02 University Of Utah Research Foundation COMPLEX LIQUID IN SITU SOLIDIFICATION COASTALITIES FOR LOCAL ADMINISTRATION OF ANTI-ANGIOGENIC AGENTS OR CHEMOTHERAPEUTIC AGENTS
CA3089480C (en) 2018-01-26 2025-05-27 Fluidx Medical Technology, Inc. APPARATUS AND METHOD FOR USING COMPLEX COACERVATES WITH IN SITU SOLIDIFICATION FOR VASCULAR OCLUSION
KR20200140817A (ko) 2018-03-02 2020-12-16 코디악 사이언시스 인코포레이티드 Il-6 항체 그리고 이의 융합 작제물 및 접합체
CN112262157A (zh) * 2018-03-09 2021-01-22 加利福尼亚大学董事会 化药抗性癌症的组合治疗
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法
CN111710425A (zh) * 2020-06-19 2020-09-25 复旦大学附属中山医院 一种免疫检查点抑制剂心脏毒性评估方法，系统及装置
AU2024210067A1 (en) * 2023-01-19 2025-08-07 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anti-her2 antibody-drug conjugate for treating breast cancer

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
JP2938569B2 (ja) 1990-08-29 1999-08-23 ジェンファーム インターナショナル，インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US20030206899A1 (en) 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
WO1993011161A1 (en) 1991-11-25 1993-06-10 Enzon, Inc. Multivalent antigen-binding proteins
ATE503496T1 (de) 1992-02-06 2011-04-15 Novartis Vaccines & Diagnostic Biosynthetisches bindeprotein für tumormarker
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
DE69233803D1 (de) 1992-10-28 2011-03-31 Genentech Inc Verwendung von vaskulären Endothelwachstumsfaktor-Antagonisten
ATE139900T1 (de) 1992-11-13 1996-07-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US5635388A (en) 1994-04-04 1997-06-03 Genentech, Inc. Agonist antibodies against the flk2/flt3 receptor and uses thereof
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
CA2226575C (en) 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
US5730977A (en) 1995-08-21 1998-03-24 Mitsui Toatsu Chemicals, Inc. Anti-VEGF human monoclonal antibody
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
NZ500078A (en) 1997-04-07 2001-10-26 Genentech Inc Humanized anti-VEGF antibodies and their use in inhibiting VEGF-induced angiogenesis in mammals
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
ATE501170T1 (de) 1997-04-07 2011-03-15 Genentech Inc Verfahren zur herstellung humanisierter antikörper durch randomisierte mutagenese
ES2244066T3 (es) 1997-06-24 2005-12-01 Genentech, Inc. Procedimiento y composiciones de glicoproteinas galactosiladas.
WO1999022764A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
ATE375365T1 (de) 1998-04-02 2007-10-15 Genentech Inc Antikörper varianten und fragmente davon
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
PT1071700E (pt) 1998-04-20 2010-04-23 Glycart Biotechnology Ag Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
EP1141024B1 (en) 1999-01-15 2018-08-08 Genentech, Inc. POLYPEPTIDE COMPRISING A VARIANT HUMAN IgG1 Fc REGION
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
AU784285B2 (en) 1999-12-24 2006-03-02 Genentech Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
DK2857516T3 (en) 2000-04-11 2017-08-07 Genentech Inc Multivalent antibodies and uses thereof
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
EP1423510A4 (en) 2001-08-03 2005-06-01 Glycart Biotechnology Ag ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY
HUP0600342A3 (en) 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US20050186208A1 (en) 2003-05-30 2005-08-25 Genentech, Inc. Treatment with anti-VEGF antibodies
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
WO2005044853A2 (en) 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
US20060009360A1 (en) 2004-06-25 2006-01-12 Robert Pifer New adjuvant composition
CN101014365B (zh) 2004-07-16 2011-04-13 辉瑞产品公司 使用抗-igf-1r抗体联合治疗非血液的恶性肿瘤
ZA200701183B (en) 2004-07-20 2008-05-28 Genentech Inc Inhibitors of angiopoietin-like 4 protein, combinations, an their use
US8367805B2 (en) * 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
WO2008077077A2 (en) * 2006-12-19 2008-06-26 Genentech, Inc. Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
EP2125016A2 (en) * 2007-02-01 2009-12-02 Genetech, Inc. Combination therapy with angiogenesis inhibitors
EP2752189B1 (en) * 2008-11-22 2016-10-26 F. Hoffmann-La Roche AG Use of anti-vegf antibody in combination with chemotherapy for treating breast cancer
CN113168667B (zh) 2019-02-27 2024-05-14 谷歌有限责任公司 灰度直方图生成

Also Published As

Publication number Publication date
AR074203A1 (es) 2010-12-29
IL243741A0 (en) 2016-04-21
US20160243227A1 (en) 2016-08-25
SI2361085T1 (sl) 2015-06-30
EP2752189A1 (en) 2014-07-09
CA2744158A1 (en) 2010-05-27
AU2009316409A1 (en) 2010-05-27
LT2752189T (lt) 2017-02-10
CY1118549T1 (el) 2017-07-12
WO2010059969A8 (en) 2011-02-03
DK2361085T3 (en) 2015-03-09
IL212998A0 (en) 2011-07-31
JP2020128389A (ja) 2020-08-27
HRP20170059T1 (hr) 2017-03-10
EP2752189B1 (en) 2016-10-26
JP2018138583A (ja) 2018-09-06
MX2011005383A (es) 2011-06-06
HUE024872T2 (en) 2016-02-29
JP2017031160A (ja) 2017-02-09
EP3178478A1 (en) 2017-06-14
HK1213177A1 (zh) 2016-06-30
KR20180117734A (ko) 2018-10-29
US20170100478A1 (en) 2017-04-13
KR20170015525A (ko) 2017-02-08
US20100143351A1 (en) 2010-06-10
HUE032693T2 (en) 2017-10-30
SG171780A1 (en) 2011-07-28
TW201609140A (zh) 2016-03-16
SI2361085T2 (sl) 2018-11-30
ES2535404T3 (es) 2015-05-11
KR101807319B1 (ko) 2017-12-11
CN105214086B (zh) 2019-09-27
WO2010059969A3 (en) 2010-08-05
EP2361085B9 (en) 2019-01-02
PL2752189T3 (pl) 2017-04-28
EP2361085A2 (en) 2011-08-31
DK2361085T4 (en) 2018-10-08
ES2611337T3 (es) 2017-05-08
PT2752189T (pt) 2017-02-02
TW201023887A (en) 2010-07-01
TWI612971B (zh) 2018-02-01
RU2531948C2 (ru) 2014-10-27
BRPI0916138A2 (pt) 2015-11-17
ES2535404T5 (es) 2018-11-19
KR20110086863A (ko) 2011-08-01
CN105214086A (zh) 2016-01-06
JP2012509889A (ja) 2012-04-26
RU2011125518A (ru) 2012-12-27
ZA201103321B (en) 2012-08-29
PL2361085T5 (pl) 2018-12-31
EP2361085B1 (en) 2015-02-25
US20150246124A1 (en) 2015-09-03
CL2011001186A1 (es) 2012-02-24
SMT201700173T1 (it) 2017-05-08
WO2010059969A2 (en) 2010-05-27
CN102223897B (zh) 2015-09-23
IL212998A (en) 2016-02-29
SI2752189T1 (sl) 2017-02-28
JP6850562B2 (ja) 2021-03-31
TWI542359B (zh) 2016-07-21
PH12014502507A1 (en) 2016-01-18
JP6041489B2 (ja) 2016-12-07
US20210093715A1 (en) 2021-04-01
CN102223897A (zh) 2011-10-19
EP2361085B2 (en) 2018-07-18
MX340724B (es) 2016-07-22
DK2752189T3 (en) 2017-01-16

Similar Documents

Publication Publication Date Title
IL212998A0 (en) Use of anti-vegf antibody in combination with chemotherapy for treating breast cancer
GB2495841B (en) Phytocannabinoids for use in the treatment of breast cancer
IL242204B (en) Monoclonal antibodies for cancer treatment
IL221058B (en) Anti-vegf antibody for the treatment of ovarian cancer
EP2734207A4 (en) NEW COMPOSITIONS AND METHOD FOR THE TREATMENT OF PROSTATE CANCER
IL199989A (en) An antibody that inhibits the dimerization of her2 and its use in cancer treatment
GB201115711D0 (en) Phyto-cannabinoids for use in the treatment of cancer
IL218108A (en) Anti-il1rap antibody for use in the treatment of leukemia
IL218011A0 (en) Combination therapy of cancer with anti-endoglin antibodies and anti-vegf agents
IL208595A0 (en) Novel antibodies used to treat cancer
WO2012018877A9 (en) Treating breast cancer with anti-il-19 antibody
IL236714A0 (en) Anti-her2 antibodies with reduced fucosylation for use in cancer therapy
IL227687B (en) Anti-alpha-v integrin antibody for use in the treatment of prostate cancer
IL219034A0 (en) Chimeric antibodies specific for cd151 and use thereof in the treatment of cancer
GB0818566D0 (en) Improvements in the chemotherapy of cancer
GB0809730D0 (en) Improvements in the chemotherapy of cancer
IL211752A0 (en) Antibody combinations and use of same for treating cancer
HK1192722A (en) Anti-erbb3 antibodies in combination with paclitaxel for treatment of gynecological cancers
GB201004712D0 (en) Improvements in the chemotherapy of cancer
GB201002199D0 (en) Improvements in the chemotherapy of cancer
IL210247A0 (en) Ccl20 - specific antibodies for cancer therapy
GB0920896D0 (en) Improvements in cancer chemotherapy